CXCL14 suppresses human papillomavirus-associated head and neck cancer through antigen-specific CD8
Journal
Oncogene
ISSN: 1476-5594
Titre abrégé: Oncogene
Pays: England
ID NLM: 8711562
Informations de publication
Date de publication:
11 2019
11 2019
Historique:
received:
01
02
2019
accepted:
26
05
2019
revised:
23
05
2019
pubmed:
17
8
2019
medline:
29
2
2020
entrez:
17
8
2019
Statut:
ppublish
Résumé
Evasion of the host immune responses is critical for both persistent human papillomavirus (HPV) infection and associated cancer progression. We have previously shown that expression of the homeostatic chemokine CXCL14 is significantly downregulated by the HPV oncoprotein E7 during cancer progression. Restoration of CXCL14 expression in HPV-positive head and neck cancer (HNC) cells dramatically suppresses tumor growth and increases survival through an immune-dependent mechanism in mice. Although CXCL14 recruits natural killer (NK) and T cells to the tumor microenvironment, the mechanism by which CXCL14 mediates tumor suppression through NK and/or T cells remained undefined. Here we report that CD8
Identifiants
pubmed: 31417179
doi: 10.1038/s41388-019-0911-6
pii: 10.1038/s41388-019-0911-6
pmc: PMC6856418
mid: NIHMS1530690
doi:
Substances chimiques
CXCL14 protein, mouse
0
Chemokines, CXC
0
Histocompatibility Antigens Class I
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
7166-7180Subventions
Organisme : NIGMS NIH HHS
ID : P20 GM103548
Pays : United States
Organisme : NIDCR NIH HHS
ID : R01 DE026125
Pays : United States
Organisme : NIAID NIH HHS
ID : T32 AI052066
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008730
Pays : United States
Références
Parkin DM. The global health burden of infection-associated cancers in the year 2002. Int J Cancer. 2006;118:3030–44.
pubmed: 16404738
Cogliano V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. Carcinogenicity of human papillomaviruses. Lancet Oncol. 2005;6:204.
pubmed: 15830458
Bosch FX, Lorincz A, Munoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244–65.
pubmed: 1769629
pmcid: 1769629
Chaturvedi AK, Engels EA, Pfeiffer RM, Hernandez BY, Xiao W, Kim E, et al. Human papillomavirus and rising oropharyngeal cancer incidence in the United States. J Clin Oncol. 2011;29:4294–301.
pubmed: 21969503
pmcid: 3221528
Westrich JA, Warren CJ, Pyeon D. Evasion of host immune defenses by human papillomavirus. Virus Res 2017;231:21–33.
pubmed: 27890631
Kuss-Duerkop SK, Westrich JA, Pyeon D. DNA tumor virus regulation of host DNA methylation and its implications for immune evasion and oncogenesis. Viruses. 2018;10:pii: E82.
pmcid: 5850389
Johnston RJ, Comps-Agrar L, Hackney J, Yu X, Huseni M, Yang Y, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8( + ) T cell effector function. Cancer Cell 2014;26:923–37.
pubmed: 25465800
Klebanoff CA, Gattinoni L, Restifo NP. CD8 + T-cell memory in tumor immunology and immunotherapy. Immunol Rev 2006;211:214–24.
pubmed: 16824130
pmcid: 1501075
Kansy BA, Concha-Benavente F, Srivastava RM, Jie HB, Shayan G, Lei Y, et al. PD-1 status in CD8( + ) T cells associates with survival and anti-PD-1 therapeutic outcomes in head and neck cancer. Cancer Res 2017;77:6353–64.
pubmed: 28904066
pmcid: 5690836
Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med 2016;14:73.
pubmed: 27151159
pmcid: 4858828
Ferris RL, Blumenschein G Jr., Fayette J, Guigay J, Colevas AD, Licitra L, et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med. 2016;375:1856–67.
pubmed: 27718784
pmcid: 5564292
Maldonado L, Teague JE, Morrow MP, Jotova I, Wu TC, Wang C, et al. Intramuscular therapeutic vaccination targeting HPV16 induces T cell responses that localize in mucosal lesions. Sci Transl Med. 2014;6:221ra13.
pubmed: 24477000
pmcid: 4086631
Cuburu N, Graham BS, Buck CB, Kines RC, Pang YY, Day PM, et al. Intravaginal immunization with HPV vectors induces tissue-resident CD8 + T cell responses. J Clin Invest. 2012;122:4606–20.
pubmed: 23143305
pmcid: 3533540
Trimble CL, Clark RA, Thoburn C, Hanson NC, Tassello J, Frosina D, et al. Human papillomavirus 16-associated cervical intraepithelial neoplasia in humans excludes CD8 T cells from dysplastic epithelium. J Immunol 2010;185:7107–14.
pubmed: 21037100
pmcid: 3075978
Lu J, Chatterjee M, Schmid H, Beck S, Gawaz M. CXCL14 as an emerging immune and inflammatory modulator. J Inflamm (Lond). 2016;13:1.
Lee HT, Liu SP, Lin CH, Lee SW, Hsu CY, Sytwu HK, et al. A crucial role of CXCL14 for promoting regulatory T cells activation in stroke. Theranostics 2017;7:855–75.
pubmed: 28382159
pmcid: 5381249
Cicchini L, Westrich JA, Xu T, Vermeer DW, Berger JN, Clambey ET, et al. Suppression of antitumor immune responses by human papillomavirus through epigenetic downregulation of CXCL14. MBio 2016;7:3.
Lyu XJ, Li HZ, Ma X, Li XT, Gao Y, Ni D, et al. Elevated S100A6 (Calcyclin) enhances tumorigenesis and suppresses CXCL14-induced apoptosis in clear cell renal cell carcinoma. Oncotarget 2015;6:6656–69.
pubmed: 25760073
pmcid: 4466641
Hu C, Lin F, Zhu G, Xue X, Ding Y, Zhao Z, et al. Abnormal hypermethylation of promoter region downregulates chemokine CXC ligand 14 expression in gastric cancer. Int J Oncol. 2013;43:1487–94.
pubmed: 23982764
Moses K, Klein JC, Mann L, Klingberg A, Gunzer M, Brandau S. Survival of residual neutrophils and accelerated myelopoiesis limit the efficacy of antibody-mediated depletion of Ly-6G + cells in tumor-bearing mice. J Leukoc Biol. 2016;99:811–23.
pubmed: 26819319
Hogquist KA, Jameson SC, Heath WR, Howard JL, Bevan MJ, Carbone FR. T cell receptor antagonist peptides induce positive selection. Cell 1994;76:17–27.
pubmed: 8287475
pmcid: 8287475
DiMaio D, Petti LM. The E5 proteins. Virology 2013;445:99–114.
pubmed: 23731971
pmcid: 3772959
Cicchini L, Blumhagen RZ, Westrich JA, Myers ME, Warren CJ, Siska C, et al. High-risk human papillomavirus E7 alters host DNA methylome and represses HLA-E expression in human keratinocytes. Sci Rep. 2017;7:3633.
pubmed: 28623356
pmcid: 5473897
Kim DH, Kim EM, Lee EH, Ji KY, Yi J, Park M, et al. Human papillomavirus 16E6 suppresses major histocompatibility complex class I by upregulating lymphotoxin expression in human cervical cancer cells. Biochem Biophys Res Commun. 2011;409:792–8.
pubmed: 21621523
Tindle RW. Immune evasion in human papillomavirus-associated cervical cancer. Nat Rev Cancer. 2002;2:59–65.
pubmed: 11902586
de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13:607–15.
van der Burg SH, de Jong A, Welters MJ, Offringa R, Melief CJ. The status of HPV16-specific T-cell reactivity in health and disease as a guide to HPV vaccine development. Virus Res 2002;89:275–84.
pubmed: 12445667
Hibma MH. The immune response to papillomavirus during infection persistence and regression. Open Virol J. 2012;6:241–8.
pubmed: 23341859
pmcid: 3547310
Woo YL, Sterling J, Damay I, Coleman N, Crawford R, van der Burg SH, et al. Characterising the local immune responses in cervical intraepithelial neoplasia: a cross-sectional and longitudinal analysis. BJOG 2008;115:1616–21. discussion 21-2
pubmed: 19035938
Handisurya A, Day PM, Thompson CD, Bonelli M, Lowy DR, Schiller JT. Strain-specific properties and T cells regulate the susceptibility to papilloma induction by Mus musculus papillomavirus 1. PLoS Pathog. 2014;10:e1004314.
pubmed: 25121947
pmcid: 4133403
Smola S, Trimble C, Stern PL. Human papillomavirus-driven immune deviation: challenge and novel opportunity for immunotherapy. Ther Adv Vaccin. 2017;5:69–82.
Da Silva DM, Woodham AW, Rijkee LK, Skeate JG, Taylor JR, Koopman ME, et al. Human papillomavirus-exposed Langerhans cells are activated by stabilized Poly-I:C. Papillomavirus Res. 2015;1:12–21.
pubmed: 26665182
pmcid: 4671084
Welters MJP, Ma W, Santegoets S, Goedemans R, Ehsan I, Jordanova ES, et al. Intratumoral HPV16-specific T cells constitute a type I-oriented tumor microenvironment to improve survival in HPV16-driven oropharyngeal cancer. Clin Cancer Res. 2018;24:634–47.
pubmed: 29018052
Bal V, McIndoe A, Denton G, Hudson D, Lombardi G, Lamb J, et al. Antigen presentation by keratinocytes induces tolerance in human T cells. Eur J Immunol. 1990;20:1893–7.
pubmed: 2120067
Liu C, Lu J, Tian H, Du W, Zhao L, Feng J, et al. Increased expression of PDL1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity. Mol Med Rep. 2017;15:1063–70.
pubmed: 28075442
pmcid: 5367331
Ran X, Yang K. Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: current status and future perspectives. Drug Des Devel Ther. 2017;11:2007–14.
pubmed: 28721019
pmcid: 5501623
Su RC, Miller RG. Stability of surface H-2K(b), H-2D(b), and peptide-receptive H-2K(b) on splenocytes. J Immunol 2001;167:4869–77.
pubmed: 11673491
de Oliveira LM, Morale MG, Chaves AA, Cavalher AM, Lopes AS, Diniz Mde O, et al. Design, immune responses and anti-tumor potential of an HPV16 E6E7 multi-epitope vaccine. PLoS ONE. 2015;10:e0138686.
pubmed: 26390407
pmcid: 4577214
Feltkamp MC, Smits HL, Vierboom MP, Minnaar RP, de Jongh BM, Drijfhout JW, et al. Vaccination with cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human papillomavirus type 16-transformed cells. Eur J Immunol. 1993;23:2242–9.
pubmed: 7690326
Herzer K, Falk CS, Encke J, Eichhorst ST, Ulsenheimer A, Seliger B, et al. Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity. J Virol 2003;77:8299–309.
pubmed: 12857899
pmcid: 165225
Tardif KD, Siddiqui A. Cell surface expression of major histocompatibility complex class I molecules is reduced in hepatitis C virus subgenomic replicon-expressing cells. J Virol 2003;77:11644–50.
pubmed: 14557650
pmcid: 229359
Glasner A, Oiknine-Djian E, Weisblum Y, Diab M, Panet A, Wolf DG, et al. Zika virus escapes NK cell detection by upregulating major histocompatibility complex class I molecules. J Virol 2017;91:22.
Kurth I, Willimann K, Schaerli P, Hunziker T, Clark-Lewis I, Moser B. Monocyte selectivity and tissue localization suggests a role for breast and kidney-expressed chemokine (BRAK) in macrophage development. J Exp Med. 2001;194:855–61.
pubmed: 11561000
pmcid: 2195966
Shurin GV, Ferris RL, Tourkova IL, Perez L, Lokshin A, Balkir L, et al. Loss of new chemokine CXCL14 in tumor tissue is associated with low infiltration by dendritic cells (DC), while restoration of human CXCL14 expression in tumor cells causes attraction of DC both in vitro and in vivo. J Immunol 2005;174:5490–8.
pubmed: 15843547
Cao X, Zhang W, Wan T, He L, Chen T, Yuan Z, et al. Molecular cloning and characterization of a novel CXC chemokine macrophage inflammatory protein-2 gamma chemoattractant for human neutrophils and dendritic cells. J Immunol 2000;165:2588–95.
pubmed: 10946286
Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–71.
pubmed: 4246418
pmcid: 4246418
Ribas A, Dummer R, Puzanov I, VanderWalde A, Andtbacka RHI, Michielin O, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy. Cell 2017;170:1109–19 e10.
pubmed: 28886381
Hata R, Izukuri K, Kato Y, Sasaki S, Mukaida N, Maehata Y, et al. Suppressed rate of carcinogenesis and decreases in tumour volume and lung metastasis in CXCL14/BRAK transgenic mice. Sci Rep. 2015;5:9083.
pubmed: 25765541
pmcid: 4357995
Miyamoto C, Maehata Y, Motohashi K, Ozawa S, Ikoma T, Hidaka K, et al. Fasudil, a Rho kinase inhibitor, suppresses tumor growth by inducing CXCL14/BRAK in head and neck squamous cell carcinoma. Biomed Res 2014;35:381–8.
pubmed: 25743344
Augsten M, Hagglof C, Olsson E, Stolz C, Tsagozis P, Levchenko T, et al. CXCL14 is an autocrine growth factor for fibroblasts and acts as a multi-modal stimulator of prostate tumor growth. Proc Natl Acad Sci USA. 2009;106:3414–9.
pubmed: 19218429
Lu J, Song G, Tang Q, Zou C, Han F, Zhao Z, et al. IRX1 hypomethylation promotes osteosarcoma metastasis via induction of CXCL14/NF-kappaB signaling. J Clin Invest. 2015;125:1839–56.
pubmed: 25822025
pmcid: 4463198
Wente MN, Mayer C, Gaida MM, Michalski CW, Giese T, Bergmann F, et al. CXCL14 expression and potential function in pancreatic cancer. Cancer Lett 2008;259:209–17.
pubmed: 18054154
Van Audenaerde JRM, Roeyen G, Darcy PK, Kershaw MH, Peeters M, Smits ELJ. Natural killer cells and their therapeutic role in pancreatic cancer: A systematic review. Pharm Ther. 2018;189:31–44.
Tarek N, Lee DA. Natural killer cells for osteosarcoma. Adv Exp Med Biol. 2014;804:341–53.
pubmed: 24924184
Pasero C, Gravis G, Granjeaud S, Guerin M, Thomassin-Piana J, Rocchi P, et al. Highly effective NK cells are associated with good prognosis in patients with metastatic prostate cancer. Oncotarget 2015;6:14360–73.
pubmed: 25961317
pmcid: 4546472
Chen L, Guo L, Tian J, He H, Marinova E, Zhang P, et al. Overexpression of CXC chemokine ligand 14 exacerbates collagen-induced arthritis. J Immunol 2010;184:4455–9.
pubmed: 20212097
pmcid: 3651906
Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol. 2003;195:346–55.
pubmed: 12704644
Nasman A, Andersson E, Nordfors C, Grun N, Johansson H, Munck-Wikland E, et al. MHC class I expression in HPV positive and negative tonsillar squamous cell carcinoma in correlation to clinical outcome. Int J Cancer. 2013;132:72–81.
pubmed: 22592660
Podolin PL, Foley JP, Carpenter DC, Bolognese BJ, Logan GA, Long E 3rd, et al. T cell depletion protects against alveolar destruction due to chronic cigarette smoke exposure in mice. Am J Physiol Lung Cell Mol Physiol. 2013;304:L312–23.
pubmed: 23292810